



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

Approved for use through October 31, 2003. GPO 2001-330.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheep

of 2

Complete If Known

<i>Application Number</i>	10/526,285
<i>Filing Date</i>	03/02/2005
<i>First Named Inventor</i>	Dharmadhikari, et al.
<i>Art Unit</i>	1614
<i>Examiner Name</i>	Michel Graffeo
<i>Attorney Docket Number</i>	006420.00001

Examiner Signature	/Michel Graffeo/	Date Considered	05/22/2006
--------------------	------------------	-----------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ***Applicant's unique citation designation number (optional).** ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. The time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Institute for form 14493/PTO				Complete If Known	
				Application Number	10/526,285
				Filing Date	03/02/2005
				First Named Inventor	Dharmadhikari, et al.
				Art Unit	1614
				Examiner Name	Michel Graffeo
Sheet	2	of	2	Attorney Docket Number	006420.00004

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
MG	3	BRITAIN, HARRY G., "Thermodynamics of Polymorphs", Polymorphism in Pharmaceutical Solids, 1999, pgs. 10-18, 290, Marcel Dekker, Inc., USA			
	4	LACHMAN, LEON, "Crystal Form", The Theory and Practice of Industrial Pharmacy, 1987, pg. 222, Varghese Publishing House, India			
	5	MARTIN, ALFRED, "Micromeritics", Physical Pharmacy, 1993, pgs. 426-429, B.I. Waverly Pvt Ltd.			
	6	U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Science, Office of Generic Drugs. Approved Drug Products with Therapeutic Equivalence Evaluations [online]. 26 th edition [retrieved 2006-3-1]. Retrieved from the Internet: <URL: http://www.fda.gov/cder/orange/obannual.pdf>, pgs. 3-241, 6-167, A-48, B-59, ADA 78			
	7	Skelaxin ® (Metaxalone), Revised August 2002, pgs. 3-6, Retrieved from the Internet: <URL: http://www.fda.gov/cder/foi/label/2002/13217s0361lbl.pdf>			
MG	8	U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Science, Office of Generic Drugs. Electronic Orange Book, Approved Drug Products with Therapeutic Equivalence Evaluations [retrieved 2006-3-1]. Retrieved from the Internet: <URL: http://www.fda.gov/cder/ob/docs/query>, 6 pages.			

Examiner Signature	/Michel Graffeo/	Date Considered	05/22/2006
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.